| Filed On | Filing |
|---|---|
| 16 Nov 2026 | SCHEDULE 13G |
| 12 Nov 2026 |
8-K: Submission of Matters to a Vote of Security Holders
Quoin Pharmaceuticals Ltd. (“we,” “us,” or the “Company”) held a Special General Meeting of Shareholders (the “Special Meeting”) on November 12, 2026. During the Special Meeting, shareholders were asked to consider and vote upon two prop... |
| 06 Nov 2026 |
8-K: Results of Operations and Financial Condition
– Reports Positive Interim Data from Ongoing Phase 2/3 Study of QRX003 in Netherton Syndrome; Primary and Key Secondary Endpoints Achieved Statistical Significance Versus Pre-Specified Alpha-Adjusted Target |
| 05 Nov 2026 | 10-Q |
| 04 Nov 2026 | EFFECT |
| 04 Nov 2026 |
8-K: Entry into a Material Definitive Agreement
Quoin Pharmaceuticals Ltd., a company organized under the laws of Israel (the “Company”), confirms its agreement (this “Agreement”) with Leerink Partners LLC (the “Agent”), as follows: |
| 04 Nov 2026 | 424B5 |
| 04 Nov 2026 | 424B5 |
| 28 Oct 2026 | FORM S-3 |
| 26 Oct 2026 |
Form 4/A: Langer Dennis, Director
Holds 49,687 shares of ADSs |
| 20 Oct 2026 |
8-K: Regulation FD Disclosure; Other Events
Quoin Pharmaceuticals Announces Publication of Peer-Reviewed Paper on QRX003 for Netherton Syndrome in Dermatology and Therapy |
| 14 Oct 2026 |
8-K: Regulation FD Disclosure; Other Events
Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Peeling Skin Syndrome |
| 07 Oct 2026 | SCHEDULE 13G/A |
| 02 Oct 2026 | DEF 14A |
| 25 Sep 2026 | EFFECT |
| 25 Sep 2026 | 424B3 |
| 22 Sep 2026 | PRE 14A |
| 22 Sep 2026 |
8-K: Regulation FD Disclosure; Other Events
First-Ever Fast Track Designation Granted for a Peeling Skin Syndrome Therapy |
| 18 Sep 2026 | FORM S-3 |
| 10 Sep 2026 | D |
Loading...